Go Pro
NASDAQ:TAOX

Synaptogenix Q2 2026 Earnings Report

Synaptogenix logo
$4.31 -0.01 (-0.32%)
As of 10:53 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Synaptogenix EPS Results

Actual EPS
-$1.83
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Synaptogenix Revenue Results

Actual Revenue
$0.09 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Synaptogenix Announcement Details

Quarter
Q2 2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Synaptogenix Earnings Headlines

A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel
See More Synaptogenix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Synaptogenix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Synaptogenix and other key companies, straight to your email.

About Synaptogenix

Synaptogenix (NASDAQ:TAOX) is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative and cognitive disorders. The company’s research has centered on synaptic function and the potential to improve memory and cognition.

Synaptogenix’s primary development program has involved bryostatin-1, an investigational drug studied for the treatment of Alzheimer’s disease and other conditions involving cognitive impairment. The company has also explored potential applications in related neurological disorders, although its product candidates are investigational and have not been approved for commercial use.

The company was formerly known as Neurotrope, Inc. and adopted the Synaptogenix name as part of a corporate rebranding. Its activities have primarily involved research and clinical development in the United States. Synaptogenix has historically traded under the Nasdaq symbol SNPX; the symbol TAOX may not correspond to the company.

View Synaptogenix Profile